Disorazol Z is a bacterially produced compound with cytotoxic activity in the sub-nanomolar range. The proof-of-concept of LHRH-receptor targeting disorazol Z conjugates for the treatment of ovarian cancer
The court has said that Cephalon‘s US Patent number 6,264,981is valid and also found that Watson Pharma’s proposed generic version of Fentora (fentanyl buccal tablet) infringes that patent.
EXTEDO intends to establish a regional network for digital cooperation between authorities and industry in Southeast Europe. CEO Tore Bergsteiner said they work closely with key regulatory authorities
Teva and Procter & Gamble intend to combine their respective market capabilities to accelerate growth of their product portfolio including over-the-counter (OTC) medicines in developed and emerging markets.
The transaction involves leasing buildings, acquiring physical equipment and assuming manufacturing processes done at the Fremont site. The facility consists of more than 200,000 square feet for laboratories,
A-CUBE, a venture capital backed company (funded by JAIC and Ben du Pont’s yet2ventures.com), uses proprietary in silico algorithms to develop various monoclonal antibodies and candidate DNA vaccines
The agreement has been signed by Sanofi-aventis with the laboratory of Gerard Karsenty to evaluate the role of osteocalcin, osteoblast-secreted peptide in diabetes management. As per the agreement,
GSK claims Solabegron is a highly selective and potent beta3-adrenoceptor agonist which is in development for the reduction of symptoms of overactive bladder (OAB) and irritable bowel syndrome
The company posted a net loss of $4.3m, compared to a net loss of $1.47m for the same period in 2009. Titan Pharma’s loss from operations was $3.98m,
Earlier, Mersana Therapeutics has released data from a Phase 1 trial evaluating XMT-1001, which showed high and prolonged plasma levels of XMT-1001 active release products and a safety
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.